



# Corrigendum: Identification of a Two-Gene (*PML-EPB41*) Signature With Independent Prognostic Value in Osteosarcoma

Shengye Liu<sup>1</sup>, Jiamei Liu<sup>2</sup>, Xuechen Yu<sup>3</sup>, Tao Shen<sup>1\*</sup> and Qin Fu<sup>1\*</sup>

<sup>1</sup> Department of Spine and Joint Surgery, Shengjing Hospital of China Medical University, Shenyang, China, <sup>2</sup> Department of Pathology, Shengjing Hospital of China Medical University, Shenyang, China, <sup>3</sup> Hammer Health Sciences Center, Columbia University Medical Center, New York, NY, United States

**Keywords:** osteosarcoma, protein-protein interaction network, gene signature, prognostic prediction, survival analysis

## A Corrigendum on

### Identification of a Two-Gene (*PML-EPB41*) Signature With Independent Prognostic Value in Osteosarcoma

by Liu, S., Liu, J., Yu, X., Shen, T., and Fu, Q. (2020). *Front. Oncol.* 9:1578. doi: 10.3389/fonc.2019.01578

In the original article, there was an error. Dataset GSE39058 was miswritten as GSE39055, 42 samples was miswritten as 47.

A correction has been made to **RESULTS, Identification of Seed Genes Based on the Coefficient of Variation in OSA, 1:**

In the present study, we established a 2-gene signature for the prognostic prediction of OSA (**Figure 1**). First, we used the GSE39058 dataset, which included 47 samples, as a training set. In this dataset, each patient sample included detailed clinicopathologic information and survival status. The coefficient of variation (CV) of each probe was calculated for all samples, and the probes with a CV >20% were considered to have the largest degree of variation among all OSA samples and were selected as the seed probes. Then, 309 probes were obtained and mapped to 308 unique genes. Next, we completed an unsupervised clustering analysis of the 42 samples by using expression profiling of the 309 probes obtained in the previous step. As shown in **Figure 2A**, the OSA samples were divided into 2 groups, and there were significant differences in gene expression levels between the groups. Survival analysis was then used to compare the outcomes of the groups: no significant difference was observed between them (log-rank test  $p \geq 0.05$ ) (**Figure 2B**).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2021 Liu, Liu, Yu, Shen and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

## OPEN ACCESS

### Approved by:

Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

### \*Correspondence:

Tao Shen  
cmu\_shentao@163.com  
Qin Fu  
cmu\_fuqin@163.com

### Specialty section:

This article was submitted to  
Cancer Molecular Targets and  
Therapeutics,  
a section of the journal  
Frontiers in Oncology

**Received:** 23 February 2021

**Accepted:** 24 February 2021

**Published:** 14 April 2021

### Citation:

Liu S, Liu J, Yu X, Shen T and Fu Q  
(2021) Corrigendum: Identification of a  
Two-Gene (*PML-EPB41*) Signature  
With Independent Prognostic Value in  
Osteosarcoma.  
*Front. Oncol.* 11:671129.  
doi: 10.3389/fonc.2021.671129